DCTH - Delcath Systems, Inc. Projected Sales Volume

Corporate company logo of Delcath Systems (DCTH)

The sales forecast model for Delcath Systems, Inc. (DCTH) demonstrates a lack of direct competitors, which protects the company's margins. High authority among physicians is based on a unique targeted liver therapy technology. The value of 0.09 reflects the baseline metric level, confirming the expansion strategy of the Hepzato system into US clinics to capture market share and grow profits from consumables.

Company Projected Revenue: Delcath Corp (DCTH) for 07/04/2022 - 11/13/2026

Analytical breakdowns for Delcath Systems, Inc.

Summary company analysis:Delcath Systems, Inc.
Brand item of Delcath Corp

This metric measures the operational resilience of the business through continuous daily revenue monitoring, allowing investors to differentiate stable growth from stagnation. Given the critical dependence of Delcath Systems, Inc. (DCTH) on sterile contract manufacturers, the assessment of the company's future sales on the GURU.Markets platform clearly demonstrates the sensitivity of commercial flows to any disruptions in outsourced component supply chains.

Direct competitors

Projected Sales Volume ONC|halozyme.com - Company Revenue Forecast|Projected Sales Volume RVMD (Revolution Medicines, Inc.)|Ascentage Pharma Group International (AAPG) - Company Expected Sales Volume|CGON - Company Projected Revenue|URGN: Company Projected Revenue|BCAX: Projected Sales Volume|Company Future Sales Volume personalis.com|ERAS (Erasca) - Projected Sales Volume|Projected Sales Volume Y-mAbs Therapeutics Inc|Company Future Sales Volume AURA (Aura Bio)|Company Projected Revenue Volume CADL|Projected Sales Volume ARAY (Accuray Incorporated)|Company Future Revenue SLS|ACTU: Company Future Sales Volume|Company Future Revenue CTOR (Citius Oncology Inc.)|tuhurabio.com (HURA) - Company Projected Revenue|TARA - Company Future Sales|Company Future Sales Volume FATE|Company Expected Sales Volume Aadi Bio WHWK|Company Projected Revenue TScan Therapeutics (TCRX)|Company Future Sales championsoncology.com|XBiotech - Company Future Sales Volume|Company Projected Revenue Volume CVM (CEL-SCI Corp.)|OS Therapies Incorporated - Projected Sales Volume|Company Expected Sales Volume Radiopharm Theranostics Ltd|artivabio.com (ARTV) - Company Projected Revenue|Company Future Sales Volume Adlai Nortye|Company Projected Revenue Veru Pharma|Tempest Therapeutics Corp (TPST) - Company Future Sales|Company Future Sales Volume XLO (Xilio Therapeutics, Inc.)|RENB (renovarobio.com) - Company Future Revenue|Projected Sales Volume MURA (Mural Oncology)|Company Future Sales Kairos Pharma Limited (KAPA)|OKUR - Company Projected Revenue|GDTC (CytoMed Therapeutics) - Company Revenue Forecast|CRIS: Projected Sales Volume|Company Future Sales Volume Apollomics|Company Future Sales Volume THAR|Advanced Biomed Corp (ADVB) - Company Future Sales|Projected Sales Volume GNPX|calidibio.com - Company Revenue Forecast|Projected Sales Volume SBFM (Sunshine Biopharma)|XBIO - Company Future Sales Volume|SLRX: Company Future Sales Volume|Purple Biotech Ltd - Company Projected Revenue Volume|AONC: Projected Sales Volume|BeiGene Ltd - Company Future Revenue|CKPT (Checkpoint Therapeutics) - Projected Sales Volume|Company Future Sales Volume Elevation Oncology Inc. (ELEV)|Projected Sales Volume ICAD|Projected Sales Volume ikenaoncology.com (IKNA)|Company Projected Revenue Notable Labs Inc. NTBL|VIRX: Company Revenue Forecast|MorphoSys AG - Projected Sales Volume|nayabiosciences.com (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume